Some treatments for osteoporosis (i.e., oral bisphosphonates, menopausal hormonal therapy, and selective estrogen receptor modulators) have suboptimal efficacy due to the difficulties in meeting treatment goals with such therapies in the highest fracture-risk patients [33]. Here, ESR1 is linked to osteoporosis.